Why the study?
Does daunorubicin improve response rates in patients with relapsed and refractory ANLL previously treated with anthracycline?
Population
21 patients with relapsed or refractory acute nonlymphoblastic leukemia previously treated with anthracycline.
Design
Case_series
Authors
Loading...
May support daunorubicin activity in anthracycline-pretreated ANLL; leaves open prospective confirmation before practice change.
Does daunorubicin improve response rates in patients with relapsed and refractory ANLL previously treated with anthracycline?
Daunorubicin remains active and can induce complete responses in patients with relapsed or refractory ANLL despite prior anthracycline exposure.
Velu et al. (1988) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: